PHARMAGENIC ENRICHMENT
LIVE

Serial Number

79389202

Owner

PolygenRx Pty Ltd

Attorney

Fatima Kassem

Filing Date

Jan 17, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PHARMAGENIC ENRICHMENT Trademark

Serial Number: 79389202 • Registration: 7772657

PHARMAGENIC ENRICHMENT is a trademark filed by PolygenRx Pty Ltd on January 17, 2024. The trademark is classified under Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

PolygenRx Pty Ltd (2 trademarks)

81-83 Campbell Street

Entity Type: 82

Trademark Details

Filing Date

January 17, 2024

Registration Date

April 29, 2025

Published for Opposition

March 11, 2025

Goods & Services

Advisory services relating to pharmaceutical products, namely, providing information to patients in the field of administering medication; provision of pharmaceutical medical information; genetic testing for medical purposes; medical advisory services relating to medical problems; medical advisory services relating to medical services; alternative medical services; arranging of medical treatment, namely, providing medical treatment of chronic diseases in the nature of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases; cardiology medical services; complementary medical services; conducting of medical examinations; general practice (GP) medical services; fitness testing, namely, medical testing for fitness evaluation; gastroenterology medical services; endocrinology medical services; dietetic counselling services, namely, dietic advisory services; medical consultancy and advisory services in relation to medical services; medical analysis of tissues for medical treatment for persons; health care consultancy services; health farm services in the nature of health spa services for health and wellness of the body and spirit offered at a health club facility; medical advice for individuals with disabilities; medical advisory services; medical analysis services relating to the treatment of patients; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services for the diagnosis and treatment of persons; medical assistance; medical care services; medical clinic services; medical consulting services relating to offshore medical services; medical counselling; medical diagnostic services; medical examination of individuals; medical health assessment services; medical services in the field of oncology; medical screening; medical services; medical treatment services, namely, medical treatment of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases; medical treatment using cultured cells; neurology medical services; oncology medical services; ophthalmology medical services; pediatric medical services; preparation of reports relating to medical matters in the nature of providing medical information to patients, medical professionals, medical providers, pharmacists, pathologists, pathology service providers, medical payers, including public and private health insurers, medical device distributors, pharmaceutical distributors, and biotechnology companies in the form of reports in the field of complex traits and disorders relating to cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases, including pharmaceutical-gene interactions, and predictions of the magnitude of response to treatments and interventions; providing medical information including online, about medical services; provision of medical assistance; provision of medical facilities, namely, leasing of equipped medical facilities that medical professionals can use on an as-needed basis; provision of medical information; provision of medical services; provision of medical treatment of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases; services for the preparation of medical reports in the nature of providing medical information to patients, medical professionals, medical providers, pharmacists, pathologists, pathology service providers, medical payers, including public and private health insurers, medical device distributors, pharmaceutical distributors, and biotechnology companies in the form of reports in the field of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 5, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 19, 2025 FICS
FINAL DISPOSITION PROCESSED
Nov 19, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 29, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 26, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 7, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 7, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 29, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 29, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Mar 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 15, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 4, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 4, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 4, 2025 TROA
REFUSAL PROCESSED BY IB
Sep 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 16, 2024 RFCS
REFUSAL PROCESSED BY MPU
Aug 16, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 8, 2024 RFCR
NON-FINAL ACTION WRITTEN
Aug 7, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 30, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 16, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 10, 2024 REPR